Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease - Scorecard - MDSpire
Advertisement
Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease
Clinical Scorecard: Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease
At a Glance
Category
Detail
Condition
Key Mechanisms
Mass spectrometry-based proteomics and metabolomics for biomarker discovery and MRD monitoring, capturing dynamic tumor biology.
Target Population
Care Setting
Key Highlights
MS-based biomarkers provide independent prognostic significance beyond R-ISS.
MS-MRD detection shows up to 1,000-fold higher sensitivity than traditional methods, allowing for earlier detection of disease progression.
MS can identify biochemical relapse 2–11 months earlier than conventional techniques, improving patient outcomes.
Guideline-Based Recommendations
Diagnosis
Management
Incorporate MS-derived biomarkers into treatment decision-making processes, such as adjusting therapy based on real-time biomarker levels.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with varying stages of multiple myeloma.
MS profiling enables personalized tracking of disease progression and treatment response.
Clinical Best Practices
Standardize bioinformatics pipelines and MS methodologies for clinical implementation.
Shift from reactive to proactive intervention strategies using MS data.
Provide ongoing training for clinicians on MS methodologies.
